LKA-651

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameLKA-651
Drug Alias NameLKA-651LKA651NOV-9
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionErythropoietin receptor modulators
TargetsErythropoietin receptor
Therapy Area/IndicationsDiabetic macular oedemaRetinal Vein OcclusionMacular Edema +[4
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoTurkey +[5
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMorphosys AgAlcon
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Active IndicationsDiabetic macular oedema
Inactive IndicationsRetinal Vein OcclusionMacular EdemaMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A